Q3 EPS Forecast for Baxter International Reduced by Analyst

Baxter International Inc. (NYSE:BAX) – Research analysts at Zacks Research lowered their Q3 2027 EPS estimates for shares of Baxter International in a report released on Thursday, March 5th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $0.65 per share for the quarter, down from their previous forecast of $0.71. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s FY2027 earnings at $2.08 EPS.

A number of other equities analysts have also recently issued reports on the company. Barclays decreased their target price on Baxter International from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Wells Fargo & Company cut their price objective on Baxter International from $21.00 to $19.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Jefferies Financial Group decreased their target price on shares of Baxter International from $21.00 to $19.00 and set a “hold” rating for the company in a report on Friday, February 13th. Morgan Stanley lowered their price objective on shares of Baxter International from $19.00 to $15.00 and set an “underweight” rating on the stock in a research report on Tuesday, December 2nd. Finally, The Goldman Sachs Group dropped their target price on Baxter International from $21.00 to $17.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Two analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.10.

Baxter International Price Performance

NYSE BAX opened at $17.45 on Monday. Baxter International has a 1 year low of $17.00 and a 1 year high of $36.57. The business’s fifty day moving average is $20.10 and its two-hundred day moving average is $20.73. The stock has a market capitalization of $8.98 billion, a P/E ratio of -9.43, a P/E/G ratio of 1.25 and a beta of 0.58. The company has a debt-to-equity ratio of 1.55, a quick ratio of 1.56 and a current ratio of 2.31.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 12th. The medical instruments supplier reported $0.44 EPS for the quarter, missing the consensus estimate of $0.53 by ($0.09). The business had revenue of $2.97 billion for the quarter, compared to analyst estimates of $2.82 billion. Baxter International had a negative net margin of 8.51% and a positive return on equity of 16.95%. The firm’s revenue for the quarter was up 8.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.58 earnings per share. Baxter International has set its FY 2026 guidance at 1.850-2.050 EPS.

Baxter International Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Friday, February 27th will be given a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, February 27th. Baxter International’s dividend payout ratio is -2.16%.

Hedge Funds Weigh In On Baxter International

Institutional investors have recently added to or reduced their stakes in the company. Dodge & Cox grew its holdings in shares of Baxter International by 10.1% during the third quarter. Dodge & Cox now owns 57,396,370 shares of the medical instruments supplier’s stock worth $1,306,915,000 after purchasing an additional 5,274,750 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Baxter International by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 13,510,205 shares of the medical instruments supplier’s stock worth $257,174,000 after purchasing an additional 972,891 shares during the period. Greenhaven Associates Inc. raised its position in shares of Baxter International by 70.0% in the 4th quarter. Greenhaven Associates Inc. now owns 10,693,223 shares of the medical instruments supplier’s stock valued at $204,347,000 after acquiring an additional 4,404,874 shares during the period. Ameriprise Financial Inc. raised its holdings in Baxter International by 1.3% in the second quarter. Ameriprise Financial Inc. now owns 7,638,629 shares of the medical instruments supplier’s stock worth $231,304,000 after purchasing an additional 97,687 shares during the period. Finally, Russell Investments Group Ltd. raised its stake in Baxter International by 35.6% during the 4th quarter. Russell Investments Group Ltd. now owns 3,410,689 shares of the medical instruments supplier’s stock worth $65,216,000 after buying an additional 894,761 shares during the period. 90.19% of the stock is owned by institutional investors.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.